Heineken warns hospitality partners of potential impact from GLP-1 weight-loss drugs

Heineken has alerted its hospitality partners about the potential negative impact of GLP-1 weight-loss drugs on beer and cider sales, as these medications may lead to reduced alcohol consumption and altered drinking habits. The company recommends that venues promote low- and no-alcohol options, smaller serving sizes, and food pairings to counteract possible declines in customer visits and spending. Heineken is actively monitoring these consumption trends and believes its product portfolio is well-suited to adapt to changing consumer preferences.